Welcome to Our Investor Relations Page
Explore key financial information, reports, and updates. Stay informed about our latest developments and learn how we create value for our shareholders. Your go-to resource for all investment-related inquiries.
Essential Information & Investor Relations
Here you’ll find essential financial reports, key dates, events, presentations, and analytical coverage to keep you informed about Biosergen’s latest developments and investment opportunities.
Financial Reports
Financial Calendar
Company presentation
Media
Interview with Tine Kold Olesen, CEO
Biosergen and Invasive Fungal Infections
Biosergen and Invasive fungal infections
Biosergen vill optimera behandling av dödliga svampinfektioner
Biosergen Introduction / Presentation
Analytical Coverage
Carlsquare
Mangold
Governance
The company is has been listed at Nasdaq First North Growth Market, Stockholm since June 24, 2021.
Carnegie Investment Bank AB (publ)
+46 (0)73 856 42 65
certifiedadviser@carnegie.se
PricewaterhouseCoopers AB
Torsgatan 21
113 97 Stockholm
PricewaterhouseCoopers AB is represented by Johan Engstam, State Authorised Public Accountant,
Largest shareholders per 2024-04-30
Board of Directors
Biosergen´s board has vast experience in biotech industry spanning from development to commercialization and the financial aspects of pharmaceutical industry.
![](https://cdn.prod.website-files.com/6697e801f5fd4521cbaaf14d/66bc4e5a8f2f1388644288eb_Anna%20Ljung.png)
![](https://cdn.prod.website-files.com/6697e801f5fd4521cbaaf14d/66b9b7d8d45c39ddd3644667_Marianne%20Kock.png)
![](https://cdn.prod.website-files.com/6697e801f5fd4521cbaaf14d/66b9b7f4bc92be6b589b0d06_Mattias%20Klintemar.png)
![](https://cdn.prod.website-files.com/6697e801f5fd4521cbaaf14d/66bc4e4d2bc25d90186c392f_Robert%20Molander.png)
Press Releases
![Surgeon mask with medical equipment](https://cdn.prod.website-files.com/6684102caa831f5ce3b46f68/66868a59f61e3197bfd147e9_myriam-zilles-7V95FwS2Ss4-unsplash.webp)
Discover the power of BSG005
Learn more about our innovative antifungal drug, BSG005. Contact Biosergen AB for further information.